Drugs and Pharmaceuticals

Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival

Author: Epeius Biotechnologies Corporation
Dateline: Mon, 22 Jun 2009

freeNewsArticles Story Summary: “SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article documents the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body.”



A R T I C L E:

SAN MARINO, Calif., June 22 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies (epeiusbiotech.com) stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article (accessible online as of June 16, 2009 in Molecular Therapy, the Official Journal of The American Society of Gene Therapy, www.nature.com/mt/) documents the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body, while sparing normal cells and healthy tissues and organs.

EpeiusFollowing the FDA's designation of Rexin-G as an Orphan Drug for the treatment of soft tissue sarcoma and osteosarcoma in 2008, the results of these two independent studies represent a major step toward gaining Accelerated Approval of Rexin-G for osteosarcoma in the United States.

"It took several years of painstaking safety studies, followed by gradual, progressive dose escalations, to the point where tumor control was consistently demonstrated, said Dr. Erlinda M. Gordon, Medical Director of Epeius Biotechnologies.

Yet the progressive development strategy has finally paid off with real dividends: (1) By establishing the overall safety of the tumor-targeted gene delivery platform first and foremost, (2) By establishing critical pharmacological thresholds of bioactivity and dose-dependent efficacy for a new class of biological anti-cancer agents in otherwise intractable cancers, and (3) By validating the potential of Rexin-G to control metastatic cancer with single-agent efficacy, whereas other targeted therapies must be used in combination with one or more toxic agents in order to achieve even marginal results. The dividends for the cancer patient can now be measured in terms of overall survival, which is considered to be the gold standard in terms of evaluating efficacy.

About Epeius Biotechnologies

Rexin-G® is commercially available for the treatment of all solid tumors in the Republic of the Philippines, and has "fast track status" as a treatment for pancreatic cancer in the United States. Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its high-performance gene delivery systems.

To learn more about ongoing clinical trials, licensing and corporate partnering opportunities, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com, or visit www.epeiusbiotech.com.

All trademarks and service marks are the property of the respective parties.

###


Copyright © 2009 by Epeius Biotechnologies Corporation and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

Story Title: Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival
• REFERENCE KEYWORDS/TERMS: treat metastatic cancers, , , Molecular Therapy, Drugs and Pharmaceuticals, , , .

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies Corporation); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Mon, 22 Jun 2009 12:45:51 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Drugs and Pharmaceuticals

Epeius Biotechnologies’ Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer

Author: Epeius Biotechnologies
Dateline: Wed, 17 Jun 2009

freeNewsArticles Story Summary: “SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate the development and expedite the review of potentially important new drugs.”



A R T I C L E:

SAN MARINO, Calif., June 17 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that its lead product, Rexin-G®, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate the development and expedite the review of potentially important new drugs.

EpeiusThe Fast Track Product designation, in particular, is granted following a critical evaluation of the "seriousness" or life-threatening nature of the unmet medical need, namely pancreatic cancer, and the potential of Rexin-G and its progressive clinical development to address this unmet need.

"This is an excellent affirmation of all that we have worked for," says Dr. Erlinda Maria Gordon, Medical Director of Epeius Biotechnologies, "and an important validation of our medical mission." Indeed, Rexin-G is the first in an entirely new class of targeted anti-cancer agents, with a sophistication that goes well beyond a simplistic antibody. Rexin-G is the flagship of tumor-targeted genetic medicine: "smart," "stealth," "selective" and "potent" nano-medicine that not only seeks out and accumulates in cancerous lesions that have spread throughout the body, but delivers a tumor-killing designer gene where it is needed most, selectively destroying tumor cells and their attendant blood supply, while sparing normal cells and healthy tissues.

As presented at the 2009 ASCO G.I. Symposium, "Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer," documenting survival benefits, without toxicity, as monotherapy, when all else fails.

The FDA's timely decision to grant Rexin-G Fast Track Product Designation is not only validating in terms of the potential of this Investigational New Drug to meet an unmet medical need, but it reflects on the design and integrity of the clinical development program of Epeius Biotechnologies. "It took years of sustained effort, but our decision to firmly establish the overall safety of repeated infusions of Rexin-G in early-stage clinical trials, before we moved on to progressively higher doses, has served us well," said Dr. Gordon. "For it was in determining the actual needs of our patients, in concordance with ongoing FDA guidance, that eventually achieved the control of tumor growth and metastasis," she added.

Remarkably, the adaptive designs of the strategic dose-escalation studies not only served to confirm the overall safety of Rexin-G and the lack of either systemic or dose-limiting toxicity, but it served to establish the critical thresholds of bioactivity and the dose-response relationships in several intractable cancers, which confirms and reveals the physiological mechanisms-of-action. These quantitative aspects of applied pharmacology are of paramount importance in establishing the clinical utility of a major new class of biological agents. Moreover, the progressive and adaptive trial designs helped to create and refine the clinical protocols for future medical praxis.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its high-performance gene delivery systems that are embodied in Rexin-G and Reximmune-C, a tumor-targeted cancer vaccine.

To learn more about ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com, or visit: www.epeiusbiotech.com.

###


Copyright © 2009 by Epeius Biotechnologies and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

Story Title: Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
• REFERENCE KEYWORDS/TERMS: FDA Fast Track Designation, , , Epeius Biotechnologies, Drugs and Pharmaceuticals, , , .

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Wed, 17 Jun 2009 06:00:17 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Drugs and Pharmaceuticals

The World’s Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers

Author: Epeius Biotechnologies
Dateline: Tue, 09 Jun 2009

freeNewsArticles Story Summary: “SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies' Rexin-G is the world's smallest hero. Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army of these tiny nano-particles seeking out and accumulating to high concentrations within the flagrant, otherwise intractable tumors with one goal in mind: to destroy the metastatic cancers from the inside.”



A R T I C L E:

SAN MARINO, Calif., June 9 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies' Rexin-G® is the world's smallest hero (www.epeiusbiotech.com). Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army of these tiny nano-particles seeking out and accumulating to high concentrations within the flagrant, otherwise intractable tumors with one goal in mind: to destroy the metastatic cancers from the inside.

Guided by nature's own disease-seeking factors (i.e., pathotropic targeting), armed with a powerful tumor-killing designer gene, and trained in the art of efficient gene delivery over aeons of evolutionary engineering, these tiny therapeutic particles represent a new paradigm in drug delivery and a new class of anti-cancer agents that exhibit profound and unprecedented single-agent efficacy in many cancers.

By selectively targeting cancers and their associated blood supply, while sparing normal cells and healthy tissues, these tiny nano-particles are inherently "smart." In performing a vital cancer surveillance function, they are uniformly "vigilant." By taking on a broad spectrum of cancers that are determined to be refractory to standard chemotherapy (i.e., ineffectual apothecary), they are exceedingly "valiant." By reducing the cancer patient's body burden and extending overall survival, they are truly "heroic." In a manner of speaking, these tiny nano-particles may well be the smallest heroes in all the world.

These "heroic" qualities are now embodied in the tumor-targeted anti-cancer agent, Rexin-G, developed by Epeius Biotechnologies. Rexin-G is currently approved for the treatment of all solid chemo-resistant tumors in the Republic of the Philippines. It has recently been granted Orphan Drug Status and market protections for three separate cancer indications by the U.S. FDA. Ongoing clinical trials in the U.S. have established the thresholds for bioactivity and the dose-dependent efficacy of Rexin-G, as well as its overall safety and lack of any dose-limiting toxicity.

Recent advanced and confirmatory clinical trials in the U.S. have demonstrated single-agent efficacy, which included both progression-free survival and overall survival. Not bad, for the world's smallest unsung hero.

For further information about Rexin-G, high-performance targeting technologies, and/or new products in development, see www.epeiusbiotech.com. For further information about current clinical trials, contact Erlinda M. Gordon, M.D., at egordon@epeiusbiotech.com.

###


Copyright © 2009 by Epeius Biotechnologies and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

Story Title: The World's Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers
• REFERENCE KEYWORDS/TERMS: anti-cancer agent, , , Orphan Drug Status, Drugs and Pharmaceuticals, , , .

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Tue, 09 Jun 2009 07:59:24 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Drugs and Pharmaceuticals

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009

Author: Epeius Biotechnologies Corporation
Dateline: Mon, 18 May 2009

freeNewsArticles Story Summary: “SAN MARINO, Calif., May 18 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies today announced the results of two related studies using Rexin-G®, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial in the U.S.”



A R T I C L E:

SAN MARINO, Calif., May 18 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies (epeiusbiotech.com) today announced the results of two related studies using Rexin-G®, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial in the U.S.

EpeiusThe Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic bone and soft tissue sarcomas (ASCO Annual Meeting 2009, #10513) demonstrated that Rexin-G was well-tolerated with no dose-limiting toxicity. Moreover, Rexin-G exhibited dose-dependent efficacy in terms of tumor control rates, progression-free survival, and overall survival, thus validating both the efficiency of the tumor-targeting technology and the pharmacological mechanisms of action.

The efficacy and safety of Rexin-G was further confirmed in a Phase II study for chemotherapy-resistant osteosarcoma. Again, in the absence of dose-limiting toxicity, Rexin-G was demonstrated to control tumor growth, prolong progression-free survival, and improve overall survival in osteosarcoma patients who have failed known therapies. It is important to note that these outstanding results, were achieved when Rexin-G was administered as monotherapy-unlike many other so-called targeted biologics where one or more toxic agents are used in combination in order to achieve even marginal results.

Based on a critical analysis of its performance in the clinic, the U.S. FDA recently granted Rexin-G Orphan Drug Status for both soft tissue sarcoma and osteosarcoma.

The results of these studies will be presented by Dr. Sant P. Chawla, Sarcoma Oncology Center, Santa Monica CA, and discussed by Dr. Katherine Janeway, Dana-Farber Cancer Institute, Boston MA on Saturday, May 30, 2009 at 5:00 p.m. EST/EDT.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its high-performance gene delivery systems that are embodied in Rexin-G and Reximmune-C, a tumor-targeted cancer vaccine.

To learn more about ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com, or visit: www.epeiusbiotech.com.


###


Copyright © 2009 by Epeius Biotechnologies Corporation and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

Story Title: Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
• REFERENCE KEYWORDS/TERMS: ASCO Annual Meeting, , , Epeius Biotechnologies, Drugs and Pharmaceuticals, , , .

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies Corporation); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Mon, 18 May 2009 12:45:19 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Drugs and Pharmaceuticals

Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial

Author: Epeius Biotechnologies
Dateline: Thu, 12 Feb 2009

freeNewsArticles Story Summary: “SAN MARINO, Calif., Feb. 12 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G. Honored as the first and so far only targeted, genetic medicine that has been validated in clinical trials worldwide (Nature Reviews, Genetics, 2007), Rexin-G is designed to seek-out and destroy metastatic cancers that are resistant to chemotherapy and which have spread throughout the body.”



A R T I C L E:

SAN MARINO, Calif., Feb. 12 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G®. Honored as the first and so far only targeted, genetic medicine that has been validated in clinical trials worldwide (Nature Reviews, Genetics, 2007), Rexin-G is designed to seek-out and destroy metastatic cancers that are resistant to chemotherapy and which have spread throughout the body.

The new website is designed to inform the general public of the basic platform biotechnologies that enable the nano-medicine to flow beyond the finest catheter, beyond the reach of the most gifted surgeon, to the very fabric of nature -- and to update prospective patients as to the current availability of Rexin-G in an increasing number of clinical trials conducted in the U.S. and the Republic of the Philippines.

The Rexin-G video is an animated tour-de-force of Science Communications. Winning both the Bronze Telly Award for film and video productions and the Platinum Aurora Award (Best of Show) for excellence in independent film-making, the Rexin-G video is a triumph of Art in the service of Science, in the service of Medicine. As one watches the artful collapsing of a tumor under the onslaught of the targeted genetic medicine, it is interesting to note that the complex mechanisms of cellular apoptosis, focal necrosis, and anti-angiogenesis were beautifully "translated" by a Native American artist/programmer by visualizing and digitizing time-lapse photography that revealed the collapsing of a pumpkin in a field. Likewise, the interactive booklet is a magical work of electronic storytelling, utilizing video stills, laser cut-outs, and other curious means to take the reader/viewer into the center of the cell to view, and to treat, cancer from the inside.

By focusing on informing society and the cancer patient of these newly-emergent, enabling biotechnologies, the accessibility of published scientific literature, and the availability of ongoing clinical trials, Epeius Biotech hopes to establish a new standard of corporate conduct and communications that recognizes the reason and intelligence of each and every cancer patient, the power and grace of an inspired medical mission, and the true value of service in an otherwise graceless age.

Rexin-G® is currently in clinical trials in the U.S. It has been granted Orphan Drug Status by the U.S. FDA for three cancer indications: (i) Pancreatic cancer, (ii) Soft Tissue Sarcoma, and (iii) Osteosarcoma. Rexin-G has recently been approved in the Philippines for the treatment of all solid tumors that are refractory to standard chemotherapy.

For general information please visit www.epeiusbiotech.com and for detailed information regarding patient eligibility for current clinical trials contact Dr. Erlinda M. Gordon, Medical Director (www.emgordon@epeiusbiotech.com).

All trademarks and service marks are the property of the respective parties.

###


Copyright © 2009 by Epeius Biotechnologies and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

Story Title: Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
• REFERENCE KEYWORDS/TERMS: tumor targeting biotech, , , metastatic cancers, Drugs and Pharmaceuticals, , , .

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Thu, 12 Feb 2009 15:58:45 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Drugs and Pharmaceuticals

Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer

Author: Epeius Biotechnologies
Dateline: Mon, 19 Jan 2009

freeNewsArticles Story Summary: “SAN MARINO, Calif., Jan. 19 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., January 2009). Rexin-G was well tolerated and there was no dose-limiting toxicity. At Dose Level I, three patients achieved stable disease with no tumor progression; and at Dose Level II, one patient had a 37 percent decrease in tumor size and five patients exhibited disease stabilization with no tumor progression.”



A R T I C L E:

Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)

SAN MARINO, Calif., Jan. 19 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies (epeiusbiotech.com) announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., Santa Monica CA, January 2009). Rexin-G was well tolerated and there was no dose-limiting toxicity. At Dose Level I, three patients achieved stable disease with no tumor progression; and at Dose Level II, one patient had a 37 percent decrease in tumor size and five patients exhibited disease stabilization with no tumor progression.

EpeiusImportantly, Rexin-G improved patient survival in a dose-dependent manner: At Dose Level I, median progression-free survival was 3 months, and median over-all survival was 5 months, while at Dose Level II, median progression-free survival was greater than 3 months, and median over-all survival was greater than 9 months.

By direct comparison with a prior low-dose Phase I safety study (Galanis et al. 2008), the new "effective doses" of Rexin-G nearly tripled the overall survival time. Thus, this current Phase I/II study defines a critical pharmacological "threshold" for Rexin-G bioactivity in the treatment of metastatic pancreatic cancer.

The present study confirms the overall safety of Rexin-G, and further demonstrates that Rexin-G monotherapy, at these defined dose levels, exhibits profound anti-tumor activity that prolongs both progression-free survival and over-all survival time in pancreatic cancer patients that had previously failed standard chemotherapy.

Rexin-G® is the world's first and so far only targeted injectable genetic medicine that has been validated in the clinic (Nature Reviews/Genetics 2007). Injected intravenously, the targeted nanoparticles are designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body. The FDA has granted Orphan Drug Status for Rexin-G for the treatment of (i) pancreatic cancer, (ii) osteosarcoma, and (iii) soft tissue sarcoma, while the Philippine BFAD has granted accelerated approval of Rexin-G for the treatment of all solid tumors that are resistant to standard chemotherapy.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its tumor-targeted gene delivery systems. To learn more about ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.

More information online: www.epeiusbiotech.com.

All trademarks acknowledged.


###


Copyright © 2009 by Epeius Biotechnologies and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

Story Title: Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer
• REFERENCE KEYWORDS/TERMS: Epeius Biotechnologies, , , ASCO GI Symposium, Drugs and Pharmaceuticals, , , .

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Mon, 19 Jan 2009 20:32:23 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Drugs and Pharmaceuticals

Silver Safety Pyramid Provides Guidelines for Safe Usage of Any Ionic Silver or Colloidal Silver Supplement

Author: Silver Safety Committee
Dateline: Thu, 08 Jan 2009

freeNewsArticles Story Summary: “FORT LAUDERDALE, Fla., Jan. 8 (SEND2PRESS NEWSWIRE) -- The Silver Safety Committee today announced its creation of the Silver Safety Pyramid, which is designed to enable anyone to easily determine safe usage levels of any dietary supplement containing silver, typically referred to as ionic silver or colloidal silver.”



A R T I C L E:

FORT LAUDERDALE, Fla., Jan. 8 (SEND2PRESS NEWSWIRE) -- The Silver Safety Committee (www.silversafety.org) today announced its creation of the Silver Safety Pyramid, which is designed to enable anyone to easily determine safe usage levels of any dietary supplement containing silver, typically referred to as ionic silver or colloidal silver.

Silver Safety PyramidThe Silver Safety Committee consists of doctors, chemistry professors and world leaders in health-freedom advocacy.

This information addresses an area of interest to thousands of people who take silver supplements for health purposes, an interest which has been largely fueled by the high-profile case of a man who turned his skin blue by consuming massive quantities of home-made colloidal silver on a daily basis for years.

According to Herbert Slavin, M.D., director of the Institute of Advanced Medicine in Lauderhill, Florida, and a member of the Committee, "This is an area where confusion and concern developed needlessly. Few things in life are as cut-and-dried as the fact that silver is completely safe when used within normal limits. The U.S. government provides a very clear guideline for the safe oral intake of silver. We've simply provided an easy method for applying that guideline to the safe use of any silver supplement product."

The U.S. Environmental Protection Agency has a guideline called the Reference Dose (RfD) for safe limits on daily intake of silver. The EPA's RfD guideline is specifically intended to keep a person's intake of silver below the level that could possibly discolor the skin. The EPA emphasizes that one would have to consume much more silver than that before one would approach the levels at which any actual adverse health effects could occur.

"Anything in excess has consequences," said Jeffrey Blumer, M.D., Ph.D., director of the Center for Drug Research, the world's largest clinical research center for pediatric drugs, and former director of the Greater Cleveland Poison Control Center. "Common substances like table salt and aspirin are harmless with normal use, but excessive intake can become toxic and even life-threatening. With normal responsible usage, silver supplements are entirely harmless to humans."

The Silver Safety Pyramid is based on the Committee's Silver Safety Guideline, which recommends that a person's intake of silver from dietary supplements be limited to 25 percent of the EPA's recommended limit for total daily intake of silver.

It utilizes the Silver Safety Calculation, a simple mathematical formula that enables a person to easily determine how much to take of any silver-containing product to remain within the safety guidelines.

The EPA RfD guideline is expressed in terms of micrograms of silver. Virtually all silver supplements, on the other hand, are labeled in terms of parts per million (ppm), which is the concentration of silver in the water, not micrograms.

With the Silver Safety Calculation, you just plug in your pounds of body weight and the ppm of silver in whatever silver supplement you're using, and it calculates the appropriate limits for you.

"The EPA guideline was challenging for people to use as a guide for silver supplements," said Committee member Donald Baird, Ph.D., professor of chemistry at Nova Southeastern University and former director of the Department of Chemistry at Florida Atlantic University. "We provided the Silver Safety Pyramid to make it very easy."

The Silver Safety Calculation is simple enough: 12 times pounds divided by ppm equals drops per day.

The Silver Safety Pyramid provides guidelines for determining safe usage limits from three perspectives:

* Daily use
* Short-term use
* Entire lifetime

"This is useful information for everyone interested in using silver for health," Dr. Baird added. "If people follow these guidelines, they can use silver supplements while remaining fully confident they are not exposing themselves to any risks whatsoever."

The Committee's website includes the Silver Safety Auto-Calculator, which automatically performs the math in the Silver Safety Pyramid for you.

The site also has an Education and FAQ section, which helps clarify the meanings of terms like ppm, ionic silver, colloidal silver, and more.

The website is www.silversafety.org.

All trademarks acknowledged.

###


Copyright © 2009 by Silver Safety Committee and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

Story Title: Silver Safety Pyramid Provides Guidelines for Safe Usage of Any Ionic Silver or Colloidal Silver Supplement
• REFERENCE KEYWORDS/TERMS: Silver Safety Committee, , , dietary supplement containing silver, Drugs and Pharmaceuticals, , , .

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Silver Safety Committee); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Thu, 08 Jan 2009 07:59:47 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Drugs and Pharmaceuticals

Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate

Author: Epeius Biotechnologies Corporation
Dateline: Tue, 16 Dec 2008

freeNewsArticles Story Summary: “SAN MARINO, Calif., Dec. 16 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body. With profound demonstrations of clinical benefit and single-agent-efficacy, as well as overall safety, Epeius Biotech continues to lead the field of clinical gene medicine with the advent of pathotropic targeting.”



A R T I C L E:

SAN MARINO, Calif., Dec. 16 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body. With profound demonstrations of clinical benefit and single-agent-efficacy, as well as overall safety, Epeius Biotech continues to lead the field of clinical gene medicine with the advent of pathotropic (or disease-seeking) targeting. These latest EU patents follow on the heels of a major clinical patent that was recently awarded in the USA for targeted gene delivery in vivo.

EpeiusTogether these clinical patents provide additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent Rexin-G®-the first and so far only tumor-targeted gene delivery system that has been successfully validated in the clinic.

Based on recent breakthroughs in tumor-targeting and nanotechnology, a new generation of powerful biological anti-cancer agents that are exceedingly precise and highly selective for diseased tissues is currently in clinical development. Anti-cancer agents such as Rexin-G® can be delivered by simple intravenous infusion, yet are programmed to seek-out and accumulate selectively in primary and metastatic lesions that have spread throughout the body, delivering a tumor-killing gene while sparing normal cells and tissues. Representing the world's first targeted genetic medicine proven to be both safe and effective in the clinic, Rexin-G® is commercially available in the Philippines-for use in all solid tumors that are refractory to standard chemotherapy-and is currently in clinical trials in the USA for several types of cancer.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about our pipeline of proprietary biotechnologies currently available for clinical development and/or new product development, please visit us at www.epeiusbiotech.com.

For more information about Rexin-G®, on-going clinical trials in the USA and abroad, and/or Epeius pathotropic (disease-seeking) gene delivery systems, please contact Erlinda M. Gordon, M.D., at egordon@epeiusbiotech.com.

###


Copyright © 2008 by Epeius Biotechnologies Corporation and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

Story Title: Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
• REFERENCE KEYWORDS/TERMS: Epeius Biotechnologies Rexin-G, , , primary cancers and metastatic lesions, Drugs and Pharmaceuticals, , , .

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies Corporation); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Tue, 16 Dec 2008 11:36:13 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Drugs and Pharmaceuticals

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma

Author: Epeius Biotechnologies Corporation
Dateline: Thu, 20 Nov 2008

freeNewsArticles Story Summary: “SAN MARINO, Calif., Nov. 20 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months.”



A R T I C L E:

Phase I/II & Confirmatory Phase II Studies

SAN MARINO, Calif., Nov. 20 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months. Analysis of safety and efficacy data showed no major toxicity, while documenting significant control of tumor growth.

epeiusAnalysis of efficacy in 42 patients with bone and soft tissue sarcoma showed a dose-response relationship between overall survival and Rexin-G which was highly significant. A confirmatory Phase II study in 17 osteosarcoma patients showed a median overall survival greater than seven months; that is, after failing standard chemotherapies.

Two patients are disease-free greater than 6 months after surgical resection of residual tumors and Rexin-G given as both neoadjuvant and adjuvant monotherapy.

These studies indicate that (i) intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controls tumor growth and improves survival in a dose-dependent manner in patients with chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems.

To learn more about Rexin-G® and Epeius Biotechnologies' pipeline of proprietary compounds currently available for clinical development, please visit us at www.epeiusbiotech.com.


###


Copyright © 2008 by Epeius Biotechnologies Corporation and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

Story Title: Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma
• REFERENCE KEYWORDS/TERMS: Epeius Biotechnologies Rexin-G, , , chemotherapy resistant metastatic cancers, Drugs and Pharmaceuticals, , , .

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies Corporation); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Thu, 20 Nov 2008 19:28:29 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Drugs and Pharmaceuticals

Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan

Author: Epeius Biotechnologies
Dateline: Wed, 29 Oct 2008

freeNewsArticles Story Summary: “SAN MARINO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world's first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body.”



A R T I C L E:

SAN MARINO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world's first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body. Clinical data from on-going studies in Los Angeles, California, indicating dose-dependent tumor control rates and survival benefits with no major toxicity in Rexin-G-treated patients prompted the extension of these clinical trials to the East Coast.

EPEIUSRexin-G has gained orphan drug status from the U.S. FDA for three clinical indications: pancreatic cancer, osteosarcoma and soft tissue sarcoma.

The New York clinical trials will be conducted at the Bruckner Oncology Center in Manhattan, New York with Howard W. Bruckner, M.D. as the Principal Investigator. Dr. Bruckner is a board certified medical oncologist who trained at Yale University School of Medicine and performed research at the NIH with specialists and collaborative groups.

Dr. Bruckner is internationally renowned for his work in pancreatic, breast, gastrointestinal, colon, and ovarian cancers and was the first medical oncologist to treat patients with Rexin-G for advanced pancreatic cancer in the United States (Int'l J Oncol 2006). He has served as an Expert Consultant and Safety Monitor for the National Surgical Adjuvant Project for Breast and Bowel Cancers Project (NSABP) sponsored by the National Cancer Institute.

For further information concerning these clinical trials in New York, please go to www.clinicaltrials.gov and search Epeius-sponsored protocols C07-104 and C07-105.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about Rexin-G and Epeius' pipeline of proprietary compounds currently available for outlicensing and clinical development, please visit us at www.epeiusbiotech.com

###


Copyright © 2008 by Epeius Biotechnologies and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

Story Title: Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan
• REFERENCE KEYWORDS/TERMS: Epeius Biotechnologies, , , Rexin-G for pancreatic cancer, Drugs and Pharmaceuticals, , , .

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Wed, 29 Oct 2008 15:11:24 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.